To improve the manufacturing efficiency of biologics, such as antibody drugs, a quality engineering framework was designed. Within this framework, critical steps and parameters in the manufacturing process were studied. Identification of these critical steps and critical parameters allows a deeper understanding of manufacturing capabilities, and suggests to process development department process control standards based on actual manufacturing capabilities as part of a PDCA (plan-do-check-act) cycle. This cycle can be applied to each manufacturing process so that it can be standardized, reducing the time needed to establish each new process.
 Junichi Matsuzaki, The present situation and the problem of biologics, The society for biotechnology, Japan, 91(9) 2013.
 Takahiro Fujimoto, Successful product development, Yuhikaku, Tokyo, 2000, pp. 105-128.
 Hirokazu Sugiyama, Business model of continuous improvement in pharmaceutical production processes, the 23rd European symposium on computer aided process engineering, 2013.
 Japan pharmaceutical manufacturers association guide book 2012-2013, Japan pharmaceutical manufacturers association, 2013, pp.
 Specification testing, manufacturing and application for antibody drugs, Science & Technology, Tokyo, 2009, pp. 134-142.
 CMC study, application and acquisition of equivalency in biopharmaceutical / antibody drugs / biosimilar, Science & Technology, Tokyo, 2011, pp. 17-25.
 Jin Seok Seo, et al, Effect of culture pH on recombinant antibody production by a new human cell line, F2N78, grown in suspension at 33.0 degree C and 37.0 degree C, Appl. Microbiol. Biotechnol., 5283, 97, 2013.
 Genichi Taguchi, Taguchi method handbook, Keisaikai, Tokyo, 2006, pp. 28-89.
 Takahiro Fujimoto, Japanese process industries, Tokyo, 2009, pp. 110-134.